Sonnet biotherapeutics provides fiscal year 2022 second quarter business and earnings update

Ind for son-1010 cleared by fda with first patient dosed in trial for advanced solid tumors son-080 on track to begin clinical studies by mid-2022 preclinical data for son-1010, son-1210, and son-1410 presented at the 2022 aacr annual meeting preclinical development of additional fhab pipeline assets progressing forward princeton, nj / accesswire / may 10, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three and six months ended march 31, 2022 and provided a business update. "we are excited to have initiated the first clinical trial with our lead fully human albumin binding pipeline asset, son-1010," said pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking